The Chris Brown Connection

The European Medicines Action has been made knowing in the evening of 5 June 2007 by Roche Registration Small of a contamination with a destructive possessions affecting the production of Viracept (nelfinavir), an antiretroviral medicament used to treat HIV-1 infected adults, adolescents and children of 3 years of stage and older. As a consequence, the fallout is being recalled from the European Splice markets, with urgent effect.

Roche has identified the level-headedness of an unexpected contaminant ethyl mesylate (also known as methane sulfonic acid ethylester) in some batches of Viracept. Ethyl mesylate is a known genotoxic burden (harmful to DNA). The level of risk to patients resulting from this contamination is difficult to measure, and is currently under more distant estimation.

As the contamination may have affected all strengths and presentations of Viracept, the company is performing a complete recall of the healing product. All packs of Viracept currently available on the market, including packs that patients may have at home, on require to be returned to the pharmacy.

Patients receiving Viracept should therefore get hold of their doctor immediately as they will have to revolution to another appropriate remedial product for their condition. Changing from Viracept to another antiretroviral medicine is likely to be based on individual resistance patterns, and may veer from dogged to acquiescent.

1. The recall affects the 27 EU Associate States and Iceland, Liechtenstein and Norway.

2. Viracept is available as an said control 50 mg/g, 250 mg tablets and 250 mg film over-coated tablets. The marketing authorisation holder is Roche Registration Narrow. More information can be establish in the European Public Assessment Report someone is concerned Viracept..

3. A entertain and accept the blame for chronicle has been prepared and can be found here.

http://www.emea.europa.eu

Approach drug information on VIRACEPT.